JonesResearch analyst Justin Walsh downgraded Vor Bio (VOR) to Hold from Buy without a price target after the company announced it is exploring a range of strategic alternatives. The firm cites the wind down of Vor’s clinical and manufacturing operations and its 95% workforce reduction for the downgrade. The company’s planned and ongoing clinical trials as well as manufacturing operations have been suspended immediately, JonesResearch points out.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VOR: